ArticleLiver cancer2026
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis.
Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Do Asian patients with HCC derive greater benefit from anti-PD-L1 plus anti-CTLA-4 therapy?Hepatobiliary surgery and nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In the preplanned interim analysis of the phase 3 CheckMate 9DW trial, first-line nivolumab plus ipilimumab demonstrated significant overall survival (OS) benefit versus lenvatinib or sorafenib (hazard ratio [HR] = 0.79; 95% confidence interval [CI]: 0.65-0.96; Methods: Patients with unresectable HCC without prior systemic therapy were randomized 1:1 to receive nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) every 3 weeks (up to 4 doses, then nivolumab 480 mg every 4 weeks) or investigator's choice of lenvatinib or sorafenib. The primary endpoint was OS. Secondary endpoints included objective response rate (ORR) and duration of response (DOR) per blinded independent central review (BICR); safety was an exploratory endpoint. Results: Fifty-six Japanese patients were randomized to nivolumab plus ipilimumab ( Conclusion: Consistent with the global population, first-line nivolumab plus ipilimumab showed clinically meaningful improvement in OS and ORR versus lenvatinib or sorafenib in Japanese patients with unresectable HCC, along with manageable safety. These results support nivolumab plus ipilimumab as a potential new first-line treatment for unresectable HCC in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.